Clinical trials: Phobic Disorders
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Social Anxiety Disorder
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of…
- Trial name
- AFFIRM-1 (NCT06510504)
- Testing
- 225 mg BNC210
- Where
- 21 sites in United States
- Volunteers
- 370 people
- Sponsor
- Bionomics Limited
Social Phobia
Treatment Of Patients With Social Anxiety Disorder
GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
- Trial name
- NCT00397722
- Testing
- GW876008, paroxetine
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 299 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2
This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during…
- Trial name
- Palisade-2 (NCT05011396)
- Testing
- PH94B Nasal Spray
- Where
- 15 sites in United States
- Volunteers
- 228 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Phobia
Social Anxiety Disorder Study Of Paroxetine
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD).
- Trial name
- NCT00318669
- Testing
- Paroxetine hydrochloride hydrate
- Where
- 16 sites in Japan
- Volunteers
- 390 people
- Sponsor
- GlaxoSmithKline
Social Phobia
Long-term Study Of Paroxetine in Women and Men
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD)
- Trial name
- SAD (NCT00264654)
- Testing
- BRL29060A, paroxetine hydrochloride hydrate
- Where
- 3 sites in Japan
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Bi-Polar Disorder, Autism Spectrum Disorder (ASD)
An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms
The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.
- Conditions
- Bi-Polar Disorder, Autism Spectrum Disorder (ASD), Major Depression Disorders, Separation Anxiety Disorder
- Trial name
- NCT07329673
- Testing
- Digital software application for cognitive performance and activity measurement (QbMobile, investigational device)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Qbtech AB
Social Anxiety Disorder (SAD)
A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder
This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).
- Trial name
- NCT07193563
- Testing
- ENX-102
- Where
- 20 sites in United States
- Volunteers
- 47 people
- Sponsor
- Engrail Therapeutics INC
Social Phobia
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.
- Trial name
- NCT00191022
- Testing
- LY686017, paroxetine
- Where
- 15 sites in United States
- Volunteers
- 185 people
- Sponsor
- Eli Lilly and Company
Social Anxiety Disorder (SAD)
A Study of ONO-1110 in Patients With Social Anxiety Disorder
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Social Anxiety Disorder
- Trial name
- NCT06805565
- Testing
- ONO-1110
- Where
- 27 sites in Japan
- Volunteers
- 115 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Social Anxiety Disorder (SAD)
A Study of NTX-1472 in Social Anxiety Disorder
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD).
- Trial name
- SOAR (NCT07323784)
- Testing
- NTX-1472
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newleos Therapeutics, Inc.